The enhanced production of PD-L1 by CDK4/6 inhibitors has now been linked to the stimulation of the transcription factor NF-kB in RB-proficient cell lines from various tumour types, as well as an increase in the protein’s durability. The gene discussed is CDK4; the disease is neoplasm.